健信超导营收下降关联方贡献50%收入 IPO前分红6000万研发费率垫底同业

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. (hereinafter referred to as "Jianxin Superconducting") is seeking an IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board, despite facing significant issues such as high customer concentration and declining revenue while its valuation has surged dramatically [1][4][7]. Group 1: Company Overview - Jianxin Superconducting, established in 2013, specializes in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of MRI equipment costs [5]. - The company has achieved a global market share of about 4.2% in the MRI superconducting magnet sector, ranking fifth globally and second domestically, and is recognized as the largest independent supplier of superconducting magnets in the world [5][6]. Group 2: Financial Performance - Jianxin Superconducting's revenue for the years 2022 to 2024 was reported as 3.59 billion, 4.51 billion, and 4.25 billion respectively, with a notable decline of 5.58% in 2024 after a growth of 25.55% in 2023 [6]. - The net profit attributable to shareholders for the same period was 346.35 million, 487.35 million, and 557.84 million, showing a significant growth in 2022 and 2023, but a slowdown in 2024 [6]. Group 3: Customer Concentration - Over 70% of Jianxin Superconducting's revenue comes from five major clients, with Fujifilm Group contributing over 40% of the revenue, indicating a high customer concentration risk [1][8]. - The top five clients' sales accounted for 73.75%, 76.68%, and 79.62% of total sales from 2022 to 2024, with a notable increase in 2024 [8][10]. Group 4: Valuation and IPO Details - Jianxin Superconducting's valuation increased from approximately 1.5 billion in 2023 to 3.46 billion for the IPO, marking a 130.67% rise despite stagnant operational performance [3][7]. - The company plans to raise 865 million through the IPO, with 90 million earmarked for working capital, raising questions about its financial strategy given its recent cash dividends totaling around 600 million [12][13]. Group 5: Research and Development - Jianxin Superconducting's R&D expenditure as a percentage of revenue was significantly lower than that of comparable companies, with rates of 5.66%, 5.42%, and 6.50% from 2022 to 2024, compared to industry averages exceeding 14% [19][20]. - The company has faced criticism for its low R&D investment relative to its peers, raising concerns about its ability to maintain competitive advantages in the market [19][20].